New book by Larry Connors Click here Improve your trading - See how
Following Dr. Oswald's presentation, the International AIDS Vaccine Initiative (IAVI), making a rare public address in Boston, will discuss its Innovation Fund, which features a three-year commitment of $10 million and is supported in part by the Bill & Melinda Gates Foundation. The IAVI will share its interest in partnering with companies in the biotechnology space.
Additionally, Dr. David E. Anderson of Variation Biotechnologies and Mustapha Leavenworth Bakali of Genocea Biosciences will each give short presentations about the current state of their respective companies. Both Variation and Genocea are well-funded private companies with investments from leading venture capital firms Clarus Ventures, Arch Venture Partners, 5AM Ventures; and Auriga Partners, Cycad Group, Alexandria Real Estate Equities, Lux Capital Management, Polaris Venture Partners and Morningside Ventures, respectively.
Following the presentations, Dr. Una Ryan, a noted vaccine expert and the former CEO of AVANT Immunotherapeutics, will moderate a panel conversation featuring all of the evening's presenters.
Keynote speaker:
Dr. Andrin Oswald, M.D., is CEO of the Novartis Vaccines and Diagnostics Division and a permanent attendee of Novartis' Executive Committee. Dr. Oswald previously held positions of assistant to the chairman and CEO; head of the Country Pharma Organization (CPO) and country president for Novartis in South Korea; and CEO of Speedel and global head of development franchises at Novartis Pharma, all with Novartis. Prior to joining Novartis in 2005, Dr. Oswald worked with McKinsey and Company, Switzerland.
Panelists:
Dr. David E. Anderson, Ph.D. is vice president of immunology and co-founder of Variation Biotechnologies, a leader in the discovery and development of vaccines to fight infectious diseases. Dr. Anderson has extensive training and has published a number of records in many fields of immunology and is a former faculty member at Harvard Medical School.
Mustapha Leavenworth Bakali is CEO at Genocea Biosciences. Over the past 20 years, Bakali has held senior operating and leadership positions at ID Biomedical, acquired by GlaxoSmithKline; PowderJect Pharmaceuticals, acquired by Chiron; Chiron Vaccines, acquired by Novartis; and Intercell AG. Previously, Bakali was COO at ID Biomedical (IDB), a Vancouver, Canada-based company focused on vaccines for influenza.
Michelle Dees is the director of the International AIDS Vaccine Initiative's (IAVI) Innovation Fund, a grant-giving mechanism targeted primarily at small- and medium-sized biotech companies. Prior to joining IAVI, Dees was manager of business development, marketing and regulatory affairs at Innovative Drug Delivery Systems (IDDS). Previously, Dees served in the Guyana Red Cross Society as a health education coordinator and director of the Red Cross Children's Home.
Dr. Una Ryan, Ph.D., O.B.E. is president and CEO of Waltham Technologies, a developer of innovative methods to clean water. Previously, Dr. Ryan held senior positions at AVANT Immunotherapeutics, Inc., T Cell Sciences Inc. and Monsanto Company. Dr. Ryan has extensive experience in the biotech industry and has served on the boards of the Biotechnology Industry Association and the Massachusetts Biotechnology Council, which she chaired from 2004-2006.
When: Monday, November 9, 2009
5:30 p.m.: Networking
6:15-8:00 p.m.: Program
8:00-9:00 p.m.: Networking reception
Where: MIT Stata Center (Building 32), Kirsch Auditorium, 32 Vassar St.,
Cambridge, MA
Registration and information:
http://www.mitforumcambridge.org/iseries/nov09.html
Pricing: Forum members: $25, Non-members: $40. Students from all
universities are free with valid ID. Pre-registration is encouraged.
MIT ENTERPRISE FORUM OF CAMBRIDGE CONTACT: Trish Fleming MIT Enterprise Forum of Cambridge 617-253-8240 Email Contact PRESS CONTACT: Brad Baker (for MIT Enterprise Forum) CHEN PR, Inc. 781-672-3118 Email Contact
SOURCE: MIT Enterprise Forum of Cambridge
http://www2.marketwire.com/mw/emailprcntct?id=337F1FAE8AEF2799 http://www2.marketwire.com/mw/emailprcntct?id=B8C1836046FE1E96
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.